

# Ian Ford

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/443719/ian-ford-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

38  
papers

2,721  
citations

17  
h-index

40  
g-index

40  
ext. papers

3,486  
ext. citations

10.3  
avg, IF

4.38  
L-index

#	Paper	IF	Citations
38	Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities.. <i>European Journal of Preventive Cardiology</i> , <b>2022</b> , 28, 1795-1806	3.9	0
37	Invasive versus medically managed acute coronary syndromes with prior bypass (CABG-ACS): insights into the registry versus randomised trial populations. <i>Open Heart</i> , <b>2021</b> , 8,	3	1
36	Invasive versus medically managed acute coronary syndromes with prior bypass (CABG-ACS): insights into the registry versus randomised trial populations. <i>Open Heart</i> , <b>2021</b> , 8, e001453	3	1
35	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. <i>European Heart Journal</i> , <b>2021</b> , 42, 1742-1756	9.5	20
34	SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. <i>European Heart Journal</i> , <b>2021</b> , 42, 2439-2454	9.5	58
33	Exercise programme to improve quality of life for patients with end-stage kidney disease receiving haemodialysis: the PEDAL RCT. <i>Health Technology Assessment</i> , <b>2021</b> , 25, 1-52	4.4	4
32	Prevalence, Incidence and Prognostic Implications of Left Bundle Branch Block in Patients with Chronic Coronary Syndromes (From the CLARIFY Registry). <i>American Journal of Cardiology</i> , <b>2021</b> , 150, 40-46	3	1
31	Fractional flow reserve derived from computed tomography coronary angiography in the assessment and management of stable chest pain: the FORECAST randomized trial. <i>European Heart Journal</i> , <b>2021</b> , 42, 3844-3852	9.5	12
30	Use of risk scores to identify lower and higher risk subsets among COMPASS-eligible patients with chronic coronary syndromes. Insights from the CLARIFY registry. <i>Clinical Cardiology</i> , <b>2021</b> , 44, 58-65	3.3	1
29	Associations of Cytomegalovirus Infection With All-Cause and Cardiovascular Mortality in Multiple Observational Cohort Studies of Older Adults. <i>Journal of Infectious Diseases</i> , <b>2021</b> , 223, 238-246	7	8
28	Simple risk models to predict cardiovascular death in patients with stable coronary artery disease. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , <b>2021</b> , 7, 287-294	4.6	1
27	International Observational Analysis of Evolution and Outcomes of Chronic Stable Angina: The Multinational CLARIFY Study. <i>Circulation</i> , <b>2021</b> , 144, 512-523	16.7	6
26	Randomized Trial-PrEscription of intraDialytic exercise to improve quALity of Life in Patients Receiving Hemodialysis. <i>Kidney International Reports</i> , <b>2021</b> , 6, 2159-2170	4.1	4
25	Stroke in Hemodialysis Patients Randomized to Different Intravenous Iron Strategies: A Prespecified Analysis from the PIVOTAL Trial.. <i>Kidney360</i> , <b>2021</b> , 2, 1761-1769	1.8	1
24	Impact of smoking on cardiovascular outcomes in patients with stable coronary artery disease. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> , 2047487320918728	3.9	8
23	Low-dose intracoronary alteplase during primary percutaneous coronary intervention in patients with acute myocardial infarction: the T-TIME three-arm RCT. <i>Efficacy and Mechanism Evaluation</i> , <b>2020</b> , 7, 1-86	1.7	
22	AuthorsVReply. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2020</b> , 31, 1654	12.7	1

21	Vitamin K Supplementation to Improve Vascular Stiffness in CKD: The K4Kidneys Randomized Controlled Trial. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2020</b> , 31, 2434-2445	12.7	23
20	Relationship between physical activity and long-term outcomes in patients with stable coronary artery disease. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> , 27, 426-436	3.9	9
19	Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. <i>European Heart Journal</i> , <b>2020</b> , 41, 347-356	9.5	20
18	Incident heart failure in outpatients with chronic coronary syndrome: results from the international prospective CLARIFY registry. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 804-812	12.3	4
17	Chronotherapy in hypertension: the devil is in the details. <i>European Heart Journal</i> , <b>2020</b> , 41, 1606-1607	9.5	11
16	Intravenous Iron Dosing and Infection Risk in Patients on Hemodialysis: A Prespecified Secondary Analysis of the PIVOTAL Trial. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2020</b> , 31, 1118-1127	12.7	33
15	Invasive Versus Medical Management in Patients With Prior Coronary Artery Bypass Surgery With a Non-ST Segment Elevation Acute Coronary Syndrome. <i>Circulation: Cardiovascular Interventions</i> , <b>2019</b> , 12, e007830	6	11
14	Vertebral artery stenting to prevent recurrent stroke in symptomatic vertebral artery stenosis: the VIST RCT. <i>Health Technology Assessment</i> , <b>2019</b> , 23, 1-30	4.4	5
13	Intravenous Iron in Patients Undergoing Maintenance Hemodialysis. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 447-458	59.2	187
12	Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data. <i>American Journal of Nephrology</i> , <b>2018</b> , 48, 260-268	4.6	21
11	Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery disease. <i>Clinical Cardiology</i> , <b>2017</b> , 40, 797-806	3.3	29
10	Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. <i>Lancet, The</i> , <b>2016</b> , 388, 2142-2152	40	261
9	Non-invasive versus invasive management in patients with prior coronary artery bypass surgery with a non-ST segment elevation acute coronary syndrome: study design of the pilot randomised controlled trial and registry (CABG-ACS). <i>Open Heart</i> , <b>2016</b> , 3, e000371	3	7
8	Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) study. <i>BMJ Open</i> , <b>2016</b> , 6, e010313	3	39
7	Ivabradine in stable coronary artery disease without clinical heart failure. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 1091-9	59.2	315
6	Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease: data from the International Observational CLARIFY Registry. <i>JAMA Internal Medicine</i> , <b>2014</b> , 174, 1651-9	11.5	84
5	The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. <i>Lancet, The</i> , <b>2012</b> , 379, 1214-24	40	658
4	Heart rate and use of beta-blockers in stable outpatients with coronary artery disease. <i>PLoS ONE</i> , <b>2012</b> , 7, e36284	3.7	60

3	Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. <i>European Heart Journal</i> , <b>2012</b> , 33, 2831-40	9.5	474
2	C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). <i>Circulation</i> , <b>2007</b> , 115, 981-9	16.7	100
1	The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. <i>American Journal of Cardiology</i> , <b>1999</b> , 84, 1192-7	3	243